ketoconazole (Nizoral, Xolegel)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Nizoral.

Indications

Contraindications

pregnancy category = c

safety in lactation = -

safety in lactation = ?

Dosage

Cream: 2% (15 g, 30 g), 2% gel (Xelogel)

Shampoo: 2% (4 oz, 120 mL).

Tabs: 200 mg.

Pharmacokinetics

elimination via liver

1/2life = 3-10 hours

Monitor

Antimicrobial activity

Adverse effects

Drug interactions

Laboratory

Mechanism of action

More general terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  3. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  4. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  5. Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 6.2 Prescriber's Letter 11(2):11 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200208&pb=PRL (subscription needed) http://www.prescribersletter.com
  7. 7.0 7.1 Prescriber's Letter 13(10): 2006 New Formulation: Xolegel (Ketoconazole Gel 2%) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=221009&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. 8.0 8.1 deprecated reference
  9. 9.0 9.1 Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com
  10. 10.0 10.1 10.2 10.3 10.4 FDA MedWatch. July 26, 2013 Nizoral (ketoconazole): Drug Safety Communication - Potentially Fatal Liver Injury, Risk of Drug Interactions and Adrenal Gland Problems. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm362672.htm
  11. 11.0 11.1 Matin K and Trump DL, Prostate Cancer, In: Geriatric Medicine: An Evidence-Based Approach, 4th ed, Cassel CK et al (eds), Springer-Verlag, New York, 2003
  12. 12.0 12.1 FDA Safety Alert. May 19, 2016 Nizoral (ketoconazole) Oral Tablets: Drug Safety Communication
    Prescribing for Unapproved Uses including Skin and Nail Infections Continues; Linked to Patient Death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm502073.htm

Database